What is the Market's View on Graphite Bio Inc (GRPH) Stock's Price and Volume Trends Tuesday?

Tuesday, March 12, 2024 12:04 PM | InvestorsObserver Analysts

Mentioned in this article

What is the Market's View on Graphite Bio Inc (GRPH) Stock's Price and Volume Trends Tuesday?

Graphite Bio Inc (GRPH) stock has gained 10.22% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Graphite Bio Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GRPH!

See Full GRPH Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GRPH Stock Today?

Graphite Bio Inc (GRPH) stock has fallen -4.69% while the S&P 500 has risen 0.83% as of 11:54 AM on Tuesday, Mar 12. GRPH is lower by -$0.17 from the previous closing price of $3.73 on volume of 462,135 shares. Over the past year the S&P 500 has gained 33.84% while GRPH has risen 44.72%. GRPH lost -$2.19 per share in the over the last 12 months.

More About Graphite Bio Inc

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. Click Here to get the full Stock Report for Graphite Bio Inc stock.